ストックスクリーナーアプリを入手
0.559
1.08%
0.006
Atyr Pharma Inc (ATYR) 最新ニュース
aTyr Pharma Company Profile & Introduction - Moomoo
aTyr Pharma(ATYR) Stock Options Chain | Quotes & News - Moomoo
Q3 Earnings Forecast for aTyr Pharma Issued By HC Wainwright - MarketBeat
Layoff Tracker: Aura, Schrödinger trim workforces - BioSpace
Why is aTyr Pharma stock gaining today? By Investing.com - Investing.com Canada
Securities Lawsuit Alert: aTyr Pharma, Inc. (ATYR) InvestorsContact Levi & Korsinsky Before December 8, 2025 - The National Law Review
aTyr Pharma Ord Shs (LIFE) Earnings Forecast: Future EPS & Revenue Growth Estimates - tradingkey.com
ATyr Pharma Announces Second Quarter 2026 Res - Moomoo
aTyr Pharma Q2 Results: EPS of $(0.11) beats estimates - scanx.trade
ATYR Looks 13.6% Overvalued on GF Value™ as Cash Supports Develo - GuruFocus
ATYR Looks 13.6% Overvalued on GF Value™ as It Restructures Amid Pulmonary Sarcoidosis Focus - GuruFocus
ATyr Pharma Sees Funding Sufficient Into Late 2028 >ATYR - moomoo.com
ATyr Pharma Fiscal Q2 Loss Narrows; Announces Restructuring Plans - marketscreener.com
Update: ATyr Pharma Fiscal Q2 Loss Narrows; Announces Restructuring Plans - Moomoo
ATyr Pharma Fiscal Q2 Loss Narrows - marketscreener.com
aTyr Pharma cuts 60% of workforce after Q2 results - Quiver Quantitative
Atyr Pharma: Q2 Earnings Snapshot - AOL.com
aTyr Pharma Inc reports results for the quarter ended June 30Earnings Summary - TradingView
aTyr Pharma Q2 net loss narrows - TradingView
aTYR Pharma posts Q2 2026 net loss of $10.3M, $58.9M cash; prioritizes efzofitimod in ILD - TradingView
aTYR PHARMA INC 2Q 2026: Net loss $(10.3M), EPS $(0.11) — 10-Q Summary - TradingView
aTyr Pharma Prioritizes Efzofitimod Program, Cuts Workforce 60% as FDA Feedback on Phase 3 Sarcoidosis Study Protocol Looms - Quiver Quantitative
ATyr Pharma, Inc. Announces CFO Changes - marketscreener.com
aTyr Pharma (ATYR) Earnings Date and Reports 2026 - MarketBeat
FMR LLC and Abigail Johnson (ATYR) disclose 2.5% ATYR Pharma ownership - Stock Titan
ATYR Q2'26 Earnings: revenue estimate is 0 USD - TradingView
LIFE|aTyr Pharma Ord Shs|Price:22.810|Chg%:+2.390 - tradingkey.com
Alerts on Ethos Technologies' Q2 results wrongly attributed to Atyr Pharma withdrawn - marketscreener.com
BRIEF-aTyr Pharma Q2 Net Income USD 19.531 Million - TradingView
aTyr Pharma Inc expected to post a loss of 12 cents a shareEarnings Preview - TradingView
aTyr Pharma (ATYR) Rises 1.25% as Shares Defend Key $0.47 Support LevelSmall Cap Breakouts - dars.gov.et
LIFE|aTyr Pharma Ord Shs|Price:20.500|Chg%:+0.080 - tradingkey.com
I am an 18-year-old ... - marketscreener.com
aTyr Pharma Inc (ATYR) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
BlackRock (ATYR holder) reports 1.8% beneficial stake in aTYR PHARMA INC - Stock Titan
ATYR|aTyr Pharma Inc|Price:0.486|Chg%:+0.006 - TradingKey
aTyr Pharma Inc (ATYR) Cash Flow - TradingKey
aTyr Pharma Inc (ATYR) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
aTyr Pharma Ord Shs (LIFE) Institutional Confidence - TradingKey
aTyr Pharma Inc (ATYR) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
aTyr Pharma Inc (ATYR) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
aTyr Pharma, Inc. Revenue Breakdown – NASDAQ:ATYR - TradingView
aTyr Pharma Ord Shs (LIFE) Shareholder Structure: Major Shareholders & Institutional Holdings - tradingkey.com
ATYR|aTyr Pharma Inc|Price:0.473|Chg%:-0.025 - TradingKey
TradingKey - TradingKey
LIFE stock trades quietly as aTyr Pharma focuses on R&D and recent loss narrows - Ad-hoc-news.de
ATYR climbs nearly 4% after session highs, even as seller pressure persists - Traders Union
ATYR News | ATYR PHARMA INC (NASDAQ:ATYR) - ChartMill
H.C. Wainwright Maintains ATyr Pharma(ATYR.US) With Hold Rating - Moomoo
aTyr Pharma (ATYR) Stock Forecast & Analyst Ratings - Moomoo
aTyr Pharma submits Phase 3 protocol for lung disease drug By Investing.com - Investing.com South Africa
aTyr Pharma submits Phase 3 protocol for lung disease drug - Investing.com
aTyr Pharma to Present Subgroup Analysis of Phase 3 - GlobeNewswire
FEDERATED HERMES, INC. Reduces Stake in aTyr Pharma Inc - GuruFocus
aTyr's 44-patient analysis shows 123.8 mL lung-function benefit - Stock Titan
aTyr Pharma Inc (HAM:471A) Stock Price & 30 Year Financial Data - GuruFocus
aTyr Pharma Inc (HAM:471A) Valuation: Modestly Overvalued - GuruFocus
JonesTrading Maintains ATyr Pharma(ATYR.US) With Hold Rating - Moomoo
ATyr Pharma stock drops around 7.5% after technical signals confirm downward trend - Traders Union
ATyr Pharma shares fall nearly 6% as bearish technical setup weighs on price - Traders Union
aTyr Pharma Inc (HAM:471A) Stock HoldersInstitutional & Insider Ownership - GuruFocus
0.52%
0.07%
大文字化:
|
ボリューム (24 時間):